Management of impending necrosis associated with soft tissue filler injections

Journal of Drugs in Dermatology

Volumn 10, Issue 9, 2011, Pages 1007-1012

  Dayan, Steven H ^a,b   Arkins, John P ^c   Mathison, Clyde C ^b  

^a Chicago Center for Facial Plastic Surgery   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c DeNova Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; DERMACYTE OXYGEN CONCENTRATE; FILLER; GLYCERYL TRINITRATE; HYALURONIC ACID; HYALURONIDASE; HYDROXYAPATITE; LEVOFLOXACIN; METHYLPREDNISOLONE; NITRO BID; OXYGEN; SOFT TISSUE FILLER; STEROID; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; ERYTHEMA; FACE; FEMALE; HUMAN; IMPENDING NECROSIS; INFECTION; LIP; MASSAGE; MOUTH ULCER; NASOLABIAL FOLD; OXYGEN THERAPY; PASTE; SKIN ATROPHY; SKIN EDEMA; SKIN INDURATION; SKIN NECROSIS; SKIN TEST; TISSUE NECROSIS; TREATMENT OUTCOME; VENOUS CONGESTION;

ADULT; ANTACIDS; ASPIRIN; COSMETIC TECHNIQUES; DURAPATITE; FEMALE; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; INJECTIONS; NECROSIS; NITROGLYCERIN; OXYGEN;

EID: 80053335957     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The American Society of Aesthetic Plastic Surgery. 2009 Statistics from The American Society of Aesthetic Plastic Surgery; 2010. Available at: http://www.surgery.org/sites/default/files/2009stats.pdf. Accessed October 27, 2010.
2. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35(suppl 2):1672-1680.
3. Gladstone HB, Cohen JL. Adverse effects when injecting facial fillers. Semin Cutan Med Surg. 2007;26(1):34-39. (Pubitemid 46349783)
4. Grunebaum LD, Bogdan Allemann I, Dayan S, Mandy S, Baumann L. The risk of alar necrosis associated with dermal filler injection. Dermatol Surg. 2009;35(suppl 2):1635-1640.
5. Schanz S, Schippert W, Ulmer A, Rassner G, Fierlbeck G. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol. 2002;146(5):928-929. (Pubitemid 34539217)
6. Coleman SR. Avoidance of arterial occlusion from injection of soft tissue fillers. Aesthet Surg J. 2002;22(6):555-557. (Pubitemid 36113598)
7. Narins RS, Jewell M, Rubin M, Cohen J, Strobos J. Clinical conference: Management of rare events following dermal fillers - focal necrosis and angry red bumps. Dermatol Surg. 2006;32(3):426-434.
8. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg. 2007;33(3):357-360. (Pubitemid 46328237)
9. Georgescu D, Jones Y, McCann JD, Anderson RL. Skin necrosis after calcium hydroxylapatite injection into the glabellar and nasolabial folds. Ophthal Plast Reconstr Surg. 2009;25(6):498-499.
10. Hanke CW, Higley HR, Jolivette DM, Swanson NA, Stegman SJ. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol. 1991;25(2 Pt 1):319-326.
11. Dayan SH, Arkins JP, Brindise R. Soft tissue fillers and biofilms. Facial Plast Surg. 2011;27(1):23-28.
12. Dayan SH. Managing Filler Complications. Merge. Allured Business Media. 2010:22-23.
13. Spear M. What are the necessary practice competencies for two providers: Dermal fillers and botulinum toxin type A injections? Plast Surg Nurs. 2010;30(4):226-246; quiz 247-228.
14. Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. 2008;34(suppl 1):92S-99S.
15. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005;31(8 Pt 1):893-897. (Pubitemid 44795682)
16. Johnsson C, Hallgren R, Elvin A, Gerdin B, Tufveson G. Hyaluronidase ameliorates rejection-induced edema. Transpl Int. 1999;12(4):235-243. (Pubitemid 29423660)
17. Maroko PR, Hillis LD, Muller JE, et al. Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. N Engl J Med. 1977;296(16):898-903. (Pubitemid 8074089)
18. Maroko PR, Libby P, Bloor CM, Sobel BE, Braunwald E. Reduction by hyaluronidase of myocardial necrosis following coronary artery occlusion. Circulation. 1972;46(3):430-437.
19. Engstrom-Laurent A, Feltelius N, Hallgren R, Wasteson A. Raised serum hyaluronate levels in scleroderma: An effect of growth factor induced activation of connective tissue cells? Ann Rheum Dis. 1985;44(9):614-620.
20. Hamerman D, Wood DD. Interleukin 1 enhances synovial cell hyaluronate synthesis. Proc Soc Exp Biol Med. 1984;177(1):205-210. (Pubitemid 15202403)
21. Heldin P, Laurent TC, Heldin CH. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem J. 1989;258(3):919-922. (Pubitemid 19083558)
22. Yaron M, Yaron I, Wiletzki C, Zor U. Interrelationship between stimulation of prostaglandin E and hyaluronate production by poly (I) . poly (C) and interferon in synovial fibroblast culture. Arthritis Rheum. 1978;21(6):694-698.
23. Suzuki M, Asplund T, Yamashita H, Heldin CH, Heldin P. Stimulation of hyaluronan biosynthesis by platelet-derived growth factor-BB and transforming growth factor-beta 1 involves activation of protein kinase C. Biochem J. 1995;307(Pt 3):817-821.
24. Nitro-BID [package insert]. Melville, NY: E. Fougera & Co.; 2010.
25. Davis SC, Cazzaniga AL, Ricotti C, et al. Topical oxygen emulsion: A novel wound therapy. Arch Dermatol. 2007;143(10):1252-1256. (Pubitemid 47607675)